Clene Inc Stock Today
| CLNNW Stock | USD 0.04 0.01 24.38% |
Performance9 of 100
| Odds Of DistressLess than 38
|
Clene is selling for under 0.0352 as of the 31st of January 2025; that is 24.38 percent increase since the beginning of the trading day. The stock's lowest day price was 0.0352. Clene has about a 38 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 2nd of November 2024 and ending today, the 31st of January 2025. Click here to learn more.
Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of various therapeutics for neurodegenerative diseases. The companys products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing and NM-PtAu7, a gold-platinum CSN therapeutic. More on Clene Inc
Moving against Clene Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Clene Stock Highlights
| President CEO | Robert MBA |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Materials, Materials (View all Sectors) |
Clene Inc (CLNNW) is traded on NASDAQ Exchange in USA. It is located in 6550 South Millrock Drive, Salt Lake City, UT, United States, 84121 and employs 82 people. Clene is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 646.98 M. Clene Inc classifies itself under Biotechnology sector and is part of Health Care industry.
Clene Inc has accumulated about 36.78 M in cash with (30.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Clene Probability Of Bankruptcy
Clene Inc Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Clene market risk premium is the additional return an investor will receive from holding Clene long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.1063 | |||
| Jensen Alpha | 2.77 | |||
| Total Risk Alpha | 0.1812 | |||
| Sortino Ratio | 0.1219 |
Clene Stock Against Markets
Clene Corporate Management
| Robert MD | Chief Officer | Profile | |
| Jeong Ted | Chief Officer | Profile | |
| Mark ESQ | Chief Officer | Profile | |
| Michael Hotchkin | Chief Officer | Profile | |
| Rob Etherington | Pres CEO | Profile | |
| Mark Mortenson | CoFounder Officer | Profile |
Additional Tools for Clene Stock Analysis
When running Clene's price analysis, check to measure Clene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clene is operating at the current time. Most of Clene's value examination focuses on studying past and present price action to predict the probability of Clene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clene's price. Additionally, you may evaluate how the addition of Clene to your portfolios can decrease your overall portfolio volatility.